• Timothy Devos, Tatjana Geukens, Alexander Schauwvlieghe, Kevin K Ariën, Cyril Barbezange, Myriam Cleeren, Veerle Compernolle, Nicolas Dauby, Daniël Desmecht, David Grimaldi, Bart N Lambrecht, Anne Luyten, Piet Maes, Michel Moutschen, Marta Romano, Lucie Seyler, Michel Toungouz Nevessignsky, Katleen Vandenberghe, Johan van Griensven, Geert Verbeke, Erika Vlieghe, Jean Cyr Yombi, Laurens Liesenborghs, Peter Verhamme, and Geert Meyfroidt.
• University Hospitals Leuven (UZ Leuven), Leuven, Belgium. timothy.devos@uzleuven.be.
• Trials. 2020 Nov 27; 21 (1): 981.

BackgroundThe COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown.MethodsDAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in the 72 h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard of care only. The active treatment group receives 2 units of 200 to 250 mL of convalescent plasma within 12 h after randomization, with a second administration of 2 units 24 to 36 h after ending the first administration. The trial aims to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and safety of the administration of convalescent plasma.DiscussionThis trial will either provide support or discourage the use of convalescent plasma as an early intervention for the treatment of hospitalized patients with COVID-19 infection.Trial RegistrationClinicalTrials.gov NCT04429854 . Registered on 12 June 2020 - Retrospectively registered.

36 keywords...

hide…